Psilocybin for End-of-Life Anxiety and Existential Distress

## The Short Answer The most consistent and dramatic finding in psilocybin research is its ability to reduce death anxiety and existential distress in people facing terminal illness. Simultaneous trials at Johns Hopkins and NYU found that a single psilocybin session produced significant, lasting reductions in anxiety, depression, and existential distress in cancer patients — with 80% of participants showing clinically meaningful improvements that persisted at 6-month follow-up. ## The Johns Hopkins and NYU Trials In 2016, two landmark studies were published simultaneously in *Journal of Psychopharmacology*: **Johns Hopkins (Griffiths et al.):** 51 cancer patients with life-threatening diagnoses received psilocybin or placebo. At 6 months, 78% of psilocybin participants showed clinically significant decreases in depressed mood and 83% showed decreases in anxiety. **NYU (Ross et al.):** 29 cancer patients received psilocybin or placebo. At 6.5-month follow-up, 60–80% of psilocybin participants showed significant reductions in anxiety and depression. ## Why Psilocybin Helps with Death Anxiety Many participants in these trials describe mystical or transcendent experiences — a sense of unity, the dissolution of the boundary between self and world, and a profound shift in their relationship with death. These experiences appear to reduce the fear of death by providing a direct experiential sense that consciousness extends beyond the individual ego. ## Frequently Asked Questions **Is psilocybin legal for end-of-life use?** Psilocybin remains Schedule I in the US. Oregon has legalized supervised psilocybin therapy (Measure 109). Some states have decriminalized possession. The FDA has granted Breakthrough Therapy designation for psilocybin in treatment-resistant depression. [See the protocol →](/research-checkout) *This article is for informational purposes only and does not constitute medical advice.*